PharmiWeb20h
Change to the Roche Enlarged Corporate Executive Committee
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Wafaa Mamilli (1967) will join the company as Chief Digital ...
Le Lézard17h
Roche receives FDA 510(k) clearance for the first blood test in the U.S. measuring Lp(a) in molar units
Approximately one in five people worldwide has elevated Lp(a) levels, putting them at increased risk of cardiovascular diseases including myocardial infarction and stroke.1The Roche Diagnostics ...
GEN10h
Maximizing Process Optimization
The effective use of ADA in bioprocessing, though, requires a multidisciplinary team, from a program lead and subject-matter ...
GlobalData on MSN18h
Decentralisation boosts diversity in trials, study finds
The analysis of numerous clinical trials saw an uptick in Indigenous American and Asian participants in decentralised trials.
F. Hoffmann-La Roche Ltd: Roche reports strong 2024 results with 7% sales growth; fourth quarter marks third straight quarter of 9% growth
Group sales grew by 7%1 at constant exchange rates (CER; 3% in CHF), driven by strong demand for both medicines and diagnostics.Excluding COVID-19, Group sales increased by 9%.
CORRECTING and REPLACING New Data Reveals DCT Components Linked to Improvements in Clinical Trial Access Among Underrepresented Communities
Please replace the release dated Jan. 28, 2025 with the following corrected version due to multiple revisions.
DiaMedica Therapeutics: Interesting Work In Treating Ischemic Stroke
DiaMedica's DM199 shows promise for Acute Ischemic Stroke, but caution is advised due to low market cap and trial outcome uncertainties. See more on DMAC here.